Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia.

@article{PedersenBjergaard2002GeneticPI,
  title={Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia.},
  author={Jens Pedersen‐Bjergaard and Mette Klarskov Andersen and Debes Hammershaimb Christiansen and Claus Nerlov},
  journal={Blood},
  year={2002},
  volume={99 6},
  pages={
          1909-12
        }
}
Therapy-related acute myeloid leukemia (t-AML) in most cases develops after chemotherapy of other malignancies and shows characteristic chromosome aberrations. Two general types of t-AML have previously been identified. One type is observed after therapy with alkylating agents and characteristically presents as therapy-related myelodysplasia with deletions or loss of the long arms of chromosomes 5 and 7 or loss of the whole chromosomes. The other type is observed after therapy with… 

Figures from this paper

Therapy-related leukemia and myelodysplasia: susceptibility and incidence
TLDR
Among patients with hematologic malignancies, long-term survivors of Hodgkin’s lymphoma are exposed to an increased risk of t-MDS/AML, particularly when receiving MOPP-based, and escalated BEACOPP regimens, and when alkylators are combined with radiotherapy.
Genetics of therapy-related myelodysplasia and acute myeloid leukemia
TLDR
Critical genetic effects underlying 5q−/−5 and 7q−-/−7 have been proposed and their association and cooperation with point mutations of p53 and AML1, respectively, extend the scenario of cooperating genetic abnormalities in MDS andAML.
Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia.
Genetic Pathways Leading to Therapy-Related Myeloid Neoplasms
TLDR
Elucidating the genetic pathways and molecular networks that are perturbed in t-MNs, may facilitate the identification of therapeutic targets that can be exploited for the development of urgently-needed targeted therapies.
Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer--an update.
TLDR
The understanding of the presentation, incidence, predisposing risk factors and pathobiology of t-MDS/t- AML is increasing, but this increased understanding has not yet been translated into improved outcomes of therapy for t- MDS/ t-AML.
Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities
TLDR
Current knowledge now makes it possible to distinguish between at least seven major genetic subgroups of MDS and AML, and has directed research towards more specific causative factors also for de novo MDSand AML.
Treatment-related myelodysplastic syndrome/acute myeloid leukemia in survivors of childhood cancer – An update
TLDR
The understanding of the presentation, incidence, predisposing risk factors and pathobiology of t-MDS/t-AML is increasing, but this increased understanding has not yet been translated into improved outcomes of therapy for t-Treatment-related myelodysplastic syndrome/acute myeloid leukemia.
Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia
TLDR
There is a significant association between class I and class II mutations possibly indicating cooperation in leukemogenesis, and between mutations of AML1 and RAS related to subsequent progression from t-MDS to t-AML.
Double therapy-related leukemia: coincidental occurrence or susceptibility for leukemia?
TLDR
Based on thorough investigations focused on the pathogenesis, several candidate molecular alterations, which may be essential for the development of t-AML/MDS, have been demonstrated.
...
...

References

SHOWING 1-10 OF 70 REFERENCES
Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia.
TLDR
The cytogenetic characteristics at diagnosis were studied in 137 consecutive cases of t-MDS and t-AML, including 22 new cases, and correlated with the clinical characteristics and the course of the disease.
Therapy-related myelodysplasia and acute myeloid leukemia. Cytogenetic characteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in the Copenhagen series.
TLDR
There may be a synergistic leukemogenic effect between the two types of drug, and in patients with germ cell tumors treated with etoposide, cisPlatin and bleomycin, reassessment suggested the risk of leukemia to increase exponentially with increasing doses of cisplatin and etopOSide.
The p53 gene in pediatric therapy-related leukemia and myelodysplasia.
TLDR
It is suggested that germline p53 mutations may predispose some children to therapy-related leukemia and myelodysplasia, but that p53mutations otherwise are infrequent in this setting.
Chromosome aberrations and prognostic factors in therapy-related myelodysplasia and acute nonlymphocytic leukemia.
TLDR
The most important predictive factor for a favorable response to intensive antileukemic chemotherapy in overt leukemia was the absence of a preceding myelodysplastic phase.
Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements.
TLDR
Younger age and not a specific type of DNA topoisomerase II inhibitor seems to predispose specifically to development of t-MDS and t-AML with translocations to chromosome band 11q23, as compared to the uncharacteristic balanced aberrations most commonly observed after therapy with alkylating agents.
Therapy-related acute promyelocytic leukemia: a report on 16 cases.
TLDR
The findings suggest that tAPL is not exceptional, and usually has several features in common with other types of therapy-related AML with specific karyotype, including solid tumor rather than hematologic malignancy as primary tumor, short interval of development, absence of known preleukemic phase.
Increase therapy-related leukemia secondary to breast cancer
TLDR
The increased proportion of therapy-related leukemia secondary to breast cancer, probably due to the use of mitoxantrone, is demonstrated on a well-defined population.
Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7.
  • M. L. Le Beau, K. Albain, J. Rowley
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1986
TLDR
Both t-MDS and t-ANLL are late complications of cytotoxic therapies that have distinctive clinical and histologic features and are associated with characteristic aberrations of chromosomes no. 5 and 7, and it seems likely that these two chromosomes contain genes involved in the pathogenesis of these hematopoietic neoplasms.
Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
TLDR
The present study and a review of the literature shows that inv(16) is an uncommon aberration in t-AML and, like balanced translocations to chromosome bands 11q23 and 21q22 and the t(15;17), often is associated with prior chemotherapy with DNA topoisomerase II inhibitors.
...
...